StreetAlpha.app
Home › Stocks › IKT

Inhibikase Therapeutics, Inc. (IKT)

$1.38
▼ −4.83%
LAST CLOSE · NOV 17

Inhibikase Therapeutics develops IKT-001, an oral drug candidate for pulmonary arterial hypertension, a rare lung blood vessel disease. It last closed at $1.38 on Nov 17, down 4.83% on the day. The average 12-month price target from 2 analysts is $4.75 (+244.2% from the last close), with a high of $8.00 and a low of $1.50.

AI Auto Pilots
Is IKT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$69.2M
EPS (diluted)
−$0.40
−185.1% vs a year ago
Free cash flow
−$49.4M
Valuation
Market cap
$193.6M
140.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$51.7M
At Sep 30
Shareholder equity
$188.8M
Shares outstanding
140.3M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.1M$3.1MFY2021FY2022: $123K$123KFY2022FY2023: $261K$261KFY2023FY2024: $0$0FY2024

From IKT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy · 1 Hold
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy · 1 Hold
2firms
1 Buy1 Hold0 Sell
Only 2 firms rated IKT in the past 90 days, not enough for a consensus
Average 12-month target
$4.75
▲ 244.2% upside

Based on 2 analysts who set a price target on IKT in the past 90 days. The average target is $4.75, with a high of $8.00 and a low of $1.50, compared with the last close of $1.38.

Low $1.50Avg $4.75High $8.00
Blue marker: last close $1.38
Highest target$8.00
Average target$4.75
Lowest target$1.50
Latest rating changes
Chardan CapitalMaintained
Nov 12Hold$1.50
HC Wainwright & Co.Reiterated
Nov 12Buy$8
Chardan CapitalInitiated
Oct 13Hold$1.50
HC Wainwright & Co.Maintained
Aug 16Buy$5
OppenheimerInitiated
Jun 10Buy$5
DateFirmActionRatingPrice target
Nov 12Chardan CapitalMaintainedHold$1.50
Nov 12HC Wainwright & Co.ReiteratedBuy$8
Oct 13Chardan CapitalInitiatedHold$1.50
Aug 16HC Wainwright & Co.MaintainedBuy$5
Jun 10OppenheimerInitiatedBuy$5
Loading…

Technical Analysis

IKT · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 13% below its 20 day and 34% below its 50 day average. It is 40% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 36), near oversold. The nearest support is the 52 week low at $1.37, and the nearest resistance the Pivot at $1.41.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 8.4%/day
Key levels
$2.6152 week high+89.1%
$2.07100 day average+50.0%
$1.93200 day average+39.9%
$1.8550 day average+34.1%
$1.70Swing high (Oct 29)+23.2%
$1.5520 day average+12.3%
$1.44Pivot R1+4.3%
$1.41Pivot+2.2%
$1.38Last close
$1.3752 week low−0.7%
$1.34Pivot S1−2.9%
Indicators
RSI (14)36.10Weak, oversold below 30Neutral
MACD-0.10Above its signal lineBullish
Stochastic13.4Near the bottom of its rangeOversold
ADX (14)39.7Trending down
Williams %R-97.2Oversold below −80, overbought above −20Oversold
CCI (20)-190.2Oversold below −100, overbought above 100Oversold
Rate of change−8.0%Change over 10 sessionsBearish
ATR (14)$0.12Typical daily range, 8.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IKT

What happened before

See how IKT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IKT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IKT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in IKT in the last 90 days.

Loading…

See today’s whale options flow across the market →

IKT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲57 buying vs 40 selling
  • ▲Held by funds +2.1 pts
  • ▲Funds holding +4
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding110106+3.8%
In funds' top 10330.0%
Held by funds90.8%88.7%+2.1 pts
New / increased13 / 4419 / 49−16.2%
Reduced / sold out32 / 823 / 14+8.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IKT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IKT is in one of them and how their past IKT trades turned out.

IKT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IKT in an article yet. Here's the latest on the wider market.

About Inhibikase Therapeutics

Inhibikase Therapeutics is a pharmaceutical company developing treatments for pulmonary arterial hypertension, a rare and progressive disease that affects the blood vessels in the lungs. Its lead candidate, IKT-001, is an oral drug related to imatinib, a cancer medicine that has been used for many years. The company is running clinical trials of IKT-001 and has not yet sold a product. Its intended patients are people living with pulmonary arterial hypertension, and the company is based in Wilmington, Delaware.

Headquarters
Wilmington, DE